

PERSONALIZING BREAST CANCER RISKS BEYOND BRCA



Join us to learn more about riskScore®: using the next generation of risk models for a more precise and personalized cancer risk

We will discuss how riskScore® is a precision medicine tool clinically validated to predict a woman's risk of developing breast cancer. We will illustrate how it analyzes family history, personal clinical risk factors, and over 80 well-studied genetic markers to predict the risk of developing breast cancer over the next 5 years and remaining lifetime. In addition, we will cover possible advances such as expanding its availability to all ancestries and leveraging it to refine the risk for mutation carriers.

PROGRAM OBJECTIVES

- 1 Describe how riskScore® analyzes over 80 well-studied genetic markers and combined with the Tyrer-Cuzick model estimates a woman's risk for developing breast cancer
- 2 Learn how the model was validated and can be utilized in clinic today
- 3 Summarize how the utilization of polygenic risk scores significantly modifies the risk of patients who carry a mutation



Dr. Thomas Slavin, MD, FACMG, DABCC
SVP, Medical Affairs - Oncology | Myriad Genetics, Inc.



7:00 - 8:00PM Eastern Time



Monday, July 20, 2020

REGISTER IN ADVANCE FOR THIS WEBINAR:

https://myriad.zoom.us/webinar/register/WN_whg5p9KEQiOUKtU94VJTXw

Note: This satellite symposium is supported by Myriad Oncology through a marketing grant. It is not part of the official education program of the ASBrS. This activity is free to all members.